What type of antibiotic is Macrobid (nitrofurantoin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Macrobid Classification

Macrobid (nitrofurantoin) is a nitrofuran derivative antibiotic specifically used for urinary tract infections. 1, 2

Drug Class and Mechanism

  • Nitrofurantoin belongs to the nitrofuran class of antimicrobials, a unique category distinct from beta-lactams, fluoroquinolones, or sulfonamides 2, 3
  • It has been in clinical use for over 60 years for treating urinary tract infections 3
  • The drug works as a urinary tract antibacterial agent whose effectiveness depends on achieving high urinary drug concentrations rather than systemic tissue levels 4

Pharmacological Characteristics

  • Nitrofurantoin is rapidly absorbed and quickly distributed into most body fluids, with a short elimination half-life 4
  • It is rapidly excreted in large amounts in bile and urine through active tubular secretion 4
  • The drug achieves therapeutic concentrations specifically in the urinary tract, with only low blood concentrations during standard dosing 4

Clinical Classification in Guidelines

  • The WHO classifies nitrofurantoin as an "Access" antibiotic in the AWaRe framework, meaning it has lower resistance potential and should be prioritized over broader-spectrum agents 5
  • Major guidelines (IDSA, AUA, WHO) recommend it as a first-line agent for uncomplicated lower urinary tract infections 6, 5
  • It is not appropriate for upper urinary tract infections (pyelonephritis) because it does not achieve adequate tissue concentrations outside the urinary tract 5, 1

Important Safety Considerations

  • The FDA has issued warnings about serious adverse effects including pulmonary reactions, hepatotoxicity, and peripheral neuropathy, particularly with long-term use (>6 months) 1
  • However, the risk of serious pulmonary or hepatic toxicity with short-term treatment is extremely low (0.001% and 0.0003%, respectively) 6
  • It is contraindicated in patients with significant renal impairment (creatinine clearance <60 mL/min) and in the last trimester of pregnancy 1, 3

References

Research

Nitrofurantoin: an update.

Obstetrical & gynecological survey, 1989

Research

[Nitrofurantoin--clinical relevance in uncomplicated urinary tract infections].

Medizinische Monatsschrift fur Pharmazeuten, 2014

Guideline

Treatment of Uncomplicated Urinary Tract Infections with Nitrofurantoin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.